摘要
目的探讨重组人白细胞介素-11结合地塞米松在原发免疫性血小板减少症(ITP)患者中的疗效。方法72例ITP患者,按入院先后顺序分为参照组和研究组,各36例。参照组实施地塞米松常规治疗,研究组实施重组人白细胞介素-11结合地塞米松治疗。比较两组患者的药物治疗起效时间、血小板(PLT)峰值、PLT达峰时间,临床疗效,治疗前后的PLT、血小板相关抗体(PAIgG)水平。结果参照组患者的药物治疗起效时间为(3.47±0.52)d,PLT达峰时间为(7.65±1.21)d,PLT峰值为(97.38±8.45)×109/L;研究组患者的药物治疗起效时间为(3.19±0.35)d,PLT达峰时间为(6.87±1.13)d,PLT峰值为(114.31±12.18)×109/L。研究组患者的药物治疗起效时间、PLT达峰时间短于参照组,PLT峰值高于参照组,差异有统计学意义(P<0.05)。研究组患者的总有效率为97.22%(35/36),高于参照组的83.33%(30/36),差异具有统计学意义(P<0.05)。治疗前,两组患者的PLT、PAIgG水平比较,差异无统计学意义(P>0.05);治疗后,两组患者的PLT水平高于本组治疗前、PAIgG水平低于本组治疗前,且研究组患者的PLT水平高于参照组、PAIgG水平低于参照组,差异具有统计学意义(P<0.05)。结论重组人白细胞介素-11结合地塞米松治疗ITP疗效显著,可同步提升患者的PLT水平且有效控制出血,存在推广价值。
Objective To discuss the efficacy of recombinant human interleukin-11 combined with dexamethasone in patients with immune thrombocytopenia(ITP).Methods A total of 72 ITP patients were divided into reference group and research group according to admission order,with 36 cases in each group.The reference group was treated with conventional dexamethasone therapy,and the research group was treated with recombinant human interleukin-11 combined with dexamethasone.The drug treatment onset time,peak platelet(PLT),PLT peak time,clinical efficacy,PLT,platelet-associated immunoglobulin(PAIgG)levels before and after treatment were compared between the two groups.Results The drug treatment onset time,PLT peak time,peak PLT of the reference group were(3.47±0.52)d,(7.65±1.21)d and(97.38±8.45)×109/L,which were(3.19±0.35)d,(6.87±1.13)d and(114.31±12.18)×109/L of the research group.The drug treatment onset time and PLT peak time of the research group were shorter than those of reference group,and peak PLT was higher than that of reference group.All the difference was statistically significant(P<0.05).The total effective rate of the research group was 97.22%(35/36),which was higher than 83.33%(30/36)of reference group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in PLT and PAIgG between the two groups(P>0.05).After treatment,the PLT of the two groups were higher than that before treatment,and PAIgG was lower than that before treatment;the PLT of research group was higher than that of reference group and PAIgG was lower than that of reference group.All the difference was statistically significant(P<0.05).Conclusion Combination of recombinant human interleukin-11 and dexamethasone has remarkable efficacy on ITP,which can simultaneously increase the PLT level of patients and effectively control bleeding.It has promotion value.
作者
刘登辉
宋洋
佘笑梅
孙莹
杨瑛
郑炜
练诗梅
LIU Deng-hui;SONG Yang;SHE Xiao-mei(Department of Hematology,Dalian Central Hospital,Dalian 116033,China)
出处
《中国实用医药》
2021年第17期157-159,共3页
China Practical Medicine
